Eli Lilly announced results from a head-to-head study comparing dulaglutide (Trulicity) to insulin glargine (Lantus; Sanofi Aventis) for hemoglobin A1c (HbA1C) reduction in patients with type 2 diabetes. The study was presented at the 75th American Diabetes Association (ADA) Scientific Sessions in Boston, MA.

The randomized, open-label, parallel-arm 26-week study enrolled 789 patients with type 2 diabetes inadequately controlled on metformin and/or a sulfonylurea primarily from China and also Korea, Mexico, and Russia. Patients received dulaglutide 0.75mg, dulaglutide 1.5mg, or insulin glargine and had an average baseline HbA1C of 8.36%; they continued to receive background treatment of metformin and/or a sulfonylurea during the study.

RELATED: Trulicity Pen Now Available for Type 2 Diabetes

Both doses of dulaglutide showed superiority to insulin glargine in HbA1C reduction (-1.7% dulaglutide 1.5mg, -1.32% dulaglutide 0.75mg, -1.15% insulin glargine) and significantly more patients reached the recommended HbA1C target of <7% with dulaglutide (65% dulaglutide 1.5mg, 54% dulaglutide 0.75mg, 41% insulin glargine). Patients treated with dulaglutide 1.5mg and 0.75mg also lost an average of 1.51kg and 0.88kg, respectively, while patients treated with insulin glargine gained on average 0.96kg.

Continue Reading

Dulaglutide is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist indicated as adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes.

For more information call (800) 545-5979 or visit Trulicity.com.